


**Product Name** : Ladarixin  
**Cat. No.** : PC-61474  
**CAS No.** : 849776-05-2  
**Molecular Formula** : C<sub>11</sub>H<sub>12</sub>F<sub>3</sub>NO<sub>6</sub>S<sub>2</sub>  
**Molecular Weight** : 375.333  
**Target** : Chemokine Receptor (CCR and CXCR)  
**Solubility** : 10 mM in DMSO



## Biological Activity

Ladarixin (DF 2156) is an allosteric, noncompetitive dual **CXCR1/2** inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC<sub>50</sub> of 0.7 nM.

Ladarixin (DF 2156) prevents PMN infiltration and tissue damage in several models of IR injury in vivo.

Ladarixin (DF 2156) abrogates motility and induces apoptosis in cultured cutaneous and uveal melanoma cells and xenografts.

Ladarixin (DF 2156) also prevents inflammation-mediated damage in MLD-STZ, prevents and reverses diabetes in NOD mice.

## References

Garau A, et al. Eur Cytokine Netw. 2006 Mar;17(1):35-41.

Citro A, et al. Diabetes. 2015 Apr;64(4):1329-40.

Kemp DM, et al. Oncotarget. 2017 Feb 28;8(9):14428-14442.

Bertini R, et al. Br J Pharmacol. 2012 Jan;165(2):436-54.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com